CTIS2024-512770-10-00进行中（未招募）1 期
UPADA-03-24
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Upadacitinib Prolonged Release Tablets 15 mg, manufactured by Sun Pharmaceutical Industries Limited, India with RINVOQ 15 mg prolonged-release tablets (Upadacitinib), Marketing Authorization Holder: AbbVie Deutschland GmbH & Co. KG Knollstraße 67061 Ludwigshafen Germany, in healthy adult, human subjects under fasting condition.CTIS2024-512773-27-00Sun Pharmaceutical Industries Limited54
进行中（未招募）
1 期
A Phase 1 Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Tarlatamab in Subjects With Small Cell Lung Cancer (DeLLphi-300)Small Cell Lung CancerMedDRA version: 21.1Level: PTClassification code: 10041068Term: Small cell lung cancer extensive stage Class: 100000004864CTIS2023-506541-39-00Amgen Inc.377
招募中
1 期
A study to learn if UCB3101 is safe and how it moves through the body of healthy participantsHealthy ParticipantsMedDRA version: 26.0Level: LLTClassification code: 10088820Term: Clinical trial healthy volunteer Class: 100000004848CTIS2023-504586-24-00CB Biopharma88
进行中（未招募）
1 期
Randomised, crossover bioequivalence clinical trial of montelukast 10 mg capsules vs montelukast 10 mg film-coated tablets, after a single oral dose administration to healthy volunteers under fasting conditions.AsthmaCTIS2023-506937-30-00aboratorios Alter S.A.36
进行中（未招募）
1 期
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose crossover bioequivalence study comparing Lamotrigine Dispersible Tablets BP 100 mg, manufactured by Sun Pharmaceutical Industries Limited, India with Lamictal (Lamotrigine) Dispersible Tablets 100 mg, Manufactured by: Delpharm Poznaÿ – Poland & Registered and Imported by: GlaxoSmithKline Brasil Ltda, in healthy adult, human subjects under fasting condition.CTIS2024-513106-62-00Sun Pharmaceutical Industries Limited30